<DOC>
	<DOCNO>NCT01291108</DOCNO>
	<brief_summary>This study evaluate safety efficacy AGN-210669 ophthalmic solution compare bimatoprost ophthalmic solution ( LumiganÂ® ) monotherapy adjunctive therapy patient primary open-angle glaucoma ocular hypertension .</brief_summary>
	<brief_title>Safety Efficacy AGN-210669 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution Patients With Open-Angle Glaucoma Ocular Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Glaucoma , Open-Angle</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Bimatoprost</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Diagnosis primary openangle glaucoma ocular hypertension eye Requires bilateral treatment IOPlowering medication Best correct visual acuity 20/100 good eye Use oral , intramuscular , intravenous topical ophthalmic corticosteroid within 2 month Inability fast 10 hour Prior refractive laser surgery ( eg , LASIK , radial keratectomy , photorefractive keratectomy ) Intraocular surgery IOPlowering laser surgery ( eg , laser trabeculoplasty ) within 6 month Current anticipate use artificial tear ocular medication aside study medication study Anticipated wear contact lens study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
</DOC>